Rennova Health, Inc.
Healthcare · Services-General Medical & Surgical Hospitals, NEC · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $18.7M | $13.0M | $3.2M | $7.2M | $16.0M | $14.5M |
| Operating income | $1.4M | −$1.4M | −$12.5M | −$17.2M | −$15.7M | −$13.2M |
| Net income | −$7.7M | −$3.3M | $5.6M | −$18.3M | −$48.0M | −$14.0M |
| Total assets | $20.3M | $20.6M | $19.6M | $12.3M | $14.7M | $14.2M |
| Total liabilities | $57.1M | $49.7M | $46.9M | $61.3M | $83.6M | $44.4M |
| Equity | −$36.8M | −$29.1M | −$27.3M | −$49.0M | −$76.5M | −$39.2M |
| EPS (diluted) | $0.00 | $-0.03 | $-913.37 | $-94.27 | $-307.74 | — |
| Shares out. | 29.93B | 36.3M | 747.0M | 9.90B | 7.51B | 500.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- 7.3%
- Net margin
- −41.4%
- Return on equity
- 21.0%
- Return on assets
- −38.2%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 281.9%
- Debt / equity
- —
- Book value / share
- $-0.00
- Revenue growth (YoY)
- 43.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- -287.20distress
- Accruals / assets
- −54.9%clean
- Beneish M-Score
- -5.06normal
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 2 warning● 5 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Operating margin is positive
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 16, 2024
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2024
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2023
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2023
- NT 10-Qmissed a reporting deadline ↗May 16, 2022
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2022
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Diamantis Christopher Eric10% owner | Aug 27, 2021 | J | 95.0M | — |
| Beach JohnDirector | Mar 6, 2018 | Grant | 3.3M | $0.00 |
| Blum Gary LDirector | Mar 6, 2018 | Grant | 3.3M | $0.00 |
| Langley TrevorDirector | Mar 6, 2018 | Grant | 3.3M | $0.00 |
| Diamantis Christopher EricDirector | Mar 6, 2018 | Grant | 3.3M | $0.00 |
| Ajami KamranDirector | Mar 6, 2018 | Grant | 3.3M | $0.00 |
| Lagan SeamusOfficer — CEO and President | Mar 6, 2018 | Grant | 26.7M | $0.00 |
| Diamantis Christopher EricDirector | Aug 15, 2017 | Grant | 100,000 | $0.00 |
| Lagan SeamusOfficer — CEO and President | Aug 15, 2017 | Grant | 200,000 | $0.00 |
| Ajami KamranDirector | Aug 15, 2017 | Grant | 100,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Other material eventNov 8, 2024
- Entered a material agreement · Completed an acquisition or dispositionSep 20, 2024
- Entered a material agreement · Regulation FD disclosure · Other material eventJun 17, 2024
- Entered a material agreementMar 26, 2024
- Entered a material agreementOct 31, 2023
- Regulation FD disclosureAug 21, 2023
- Regulation FD disclosureApr 24, 2023
- Regulation FD disclosureFeb 23, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.